← 返回

一种利用非侵入性细胞-唾液采样和快速高灵敏 ELISA 免疫测定检测口腔癌生物标志物的新方法:一项人体初步研究

英文原题:A new method for oral cancer biomarkers detection with a non-invasive cyto-salivary sampling and rapid-highly sensitive ELISA immunoassay: a pilot study in humans.

查看英文原题

A new method for oral cancer biomarkers detection with a non-invasive cyto-salivary sampling and rapid-highly sensitive ELISA immunoassay: a pilot study in humans.

PubMed 2023/07/06(内容时间) Front Immunol Q1 · IF 7(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

研究思路按摘要原文分段

口腔鳞状细胞癌(OSCC)约占口腔恶性肿瘤的90%,5年死亡率接近50%。由于现有筛查技术效果不佳,全部口腔癌中有相当一部分(70%)在晚期才被诊断。因此,改进筛查技术迫在眉睫。诊断金标准是组织活检并结合组织学和免疫组化评估。该方法存在一些局限性。活检具有侵入性,且组织病理学评估是半定量的,无法可靠确定靶标的绝对丰度。此外,组织经过高度处理,可能导致自然状态信息的丢失。利用细胞刷采集的组织/细胞碎片寻找经典和新型临床生物标志物,是OSCC早期检测和诊断的一种极具希望的技术,因为其采样无创且采集方法简便。

我们在此分析了通过创新性高灵敏度ELISA技术从15例已确诊OSCC患者口腔采集的细胞刷活检样本,以验证该方法是否可为OSCC的检测、诊断和预后提供有用信息。为此,我们选择了六种生物标志物,这些标志物已在临床实践中用于OSCC诊断(EGFR、Ki67、p53),或基于近期科学和临床数据选定,这些数据表明它们存在于或过表达于发生转化的细胞中,并可能作为免疫检查点阻断治疗中的分子靶点(PD-L1、HLA-E、B7-H6)。

所选肿瘤生物标志物在肿瘤核心中高表达,而在同一患者采集的健康组织中几乎为阴性。这些差异具有高度统计学显著性,且与使用金标准检测获得的结果一致,清楚表明所提出的方法,即通过定制ELISA技术分析生物标志物,具有很强的可靠性。

这些初步数据表明,这种非侵入性快速表型分析技术可作为口腔病变表型分析的筛查工具,并通过精确指示病变特征来支持临床实践,同时也为针对OSCC患者应用新的抗肿瘤治疗(如免疫治疗)提供了前景。

展开英文摘要原文

Here we analyzed cytobrush biopsies samples collected from the oral cavity of 15 patients with already diagnosed OSCC by applying an innovative high-sensitivity ELISA technique, in order to verify if this approach may provide useful information for detection, diagnosis, and prognosis of OSCC. To this end, we selected six biomarkers, already used in clinical practice for the diagnosis of OSCC (EGFR, Ki67, p53) or selected based on recent scientific and clinical data which indicate their presence or over-expression in cells undergoing transformation and their role as possible molecular targets in immunecheckpoints blockade therapies (PD-L1, HLA-E, B7-H6).

The selected tumor biomarkers were highly expressed in the tumor core, while were virtually negative in healthy tissue collected from the same patients. These differences were highly statistically significant and consistent with those obtained using the gold standard test clearly indicating that the proposed approach, i.e. analysis of biomarkers by a custom ELISA technique, is strongly reliable. DISCUSSION: These preliminary data suggest that this non-invasive rapid phenotyping technique could be useful as a screening tool for phenotyping oral lesions and support clinical practice by precise indications on the characteristics of the lesion, also with a view to the application of new anti-tumor treatments, such as immunotherapy, aimed at OSCC patients.

论文信息

作者
Rebaudi F、De Rosa A、Greppi M、Pistilli R、Pucci R、Govoni FA、Iacoviello P、Broccolo F
单位
Department of Experimental Medicine (DIMES), University of Genova, Genova, Italy.Italy
文献类型
非美国政府资助研究
期刊
Frontiers in immunology2023
原文标识
PubMed 37483588 · DOI 10.3389/fimmu.2023.1216107